Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00353912 · ClinicalTrials.gov registry record · Phase 3
Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Black Patients With Stage II Hypertension
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 571
- Enrollment target
NCT00353912 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 571 participants.
The verdict
NCT00353912, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 571 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the blood pressure lowering effects of a valsartan/amlodipine combination treatment and amlodipine monotherapy for the treatment of Black stage II hypertensive patients (MSSBP ≥ 160 mmHg).
Interventions
- DRUG valsartan + amlodipine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 571 participants |
| Start Date | 2006-06 |
| Est. Completion | 2007-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00353912
The ClinicalTrials.gov registry entry for NCT00353912 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 571 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which valsartan + amlodipine is the first listed.
NCT00353912 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00353912 about?
NCT00353912 is a clinical study titled "Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Black Patients With Stage II Hypertension". The purpose of this study is to evaluate the blood pressure lowering effects of a valsartan/amlodipine combination treatment and amlodipine monotherapy for the treatment of Black stage II hypertensive patients (MSSBP ≥ 160 mmHg).
What is the current status of trial NCT00353912?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 571 participants. The study started on 2006-06. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00353912?
The interventions under investigation include: valsartan + amlodipine (DRUG).
Who is sponsoring clinical trial NCT00353912?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.